article thumbnail

Chatbot opens computational chemistry to nonexperts

Science Daily: Pharmacology News

A web platform uses a chatbot to enable any chemist -- including undergraduate chemistry majors -- to configure and execute complex quantum mechanical simulations through chatting.

article thumbnail

AI in Drug Discovery - A Highly Opinionated Literature Review (Part III)

Practical Cheminformatics

Following up on Part I and Part II, the third post in this series is a collection of review articles published in 2023 that I found helpful.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Data-Driven Future of Drug Development

DrugBank

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle. These complex molecules require precise engineering to ensure optimal efficacy and safety.

article thumbnail

Sygnature Discovery and Daewoong Pharma announce research collaboration

Sygnature Discovery

Sygnature Discovery will provide integrated drug discovery support using specialist fragment-based drug discovery (FBDD) and virtual high throughput screening (vHTS) expertise from its medicinal chemistry, biology, and computational science teams.

article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

For example, in the screening stage of a project we are trying to find initial starting points for optimisation by our medicinal and computational chemistry colleagues. I think as a researcher you have to be honest and transparent about your data, and always do the best science that you possibly can do.

article thumbnail

Sygnature Discovery accelerates global growth with major North American acquisition

Sygnature Discovery

Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. Marc Lebel, Pharm.

article thumbnail

Lead Pharma enters into a Research Collaboration and License Agreement with Roche to Develop Oral Small Molecules for Immune Mediated Diseases

The Pharma Data

Our rigorous target selection process, translational screening cascade, and smart medicinal chemistry have been essential to bring this project to this stage. Lead Pharma is headquartered at Pivot Park, the biopharmaceutical life sciences campus in Oss, the Netherlands. ” About Immune Mediated Diseases.